NewsEpisurf Medical: Interim Report 1 July – 30 September 2017

Third quarter 2017, compared to 2016, Group

  • 50% growth in orders for Episealer® knee implants during the quarter with 42 (28) approved orders. Invoicing taking place at delivery during both Q3 and Q4 2017
  • Group net sales increased by 1% to SEK 520,284 (516,641)
  • Other operating income amounted to SEK 97,716 (–)
  • Loss before tax amounted to SEK –13,518,593 (–15,042,517)
  • Earnings per share (weighted average) amounted to SEK –0.45 (–0.79)

Significant events during the third quarter

  • 100 patient multi-center study of the Episealer® knee implant fully recruited
  • Episurf Medical’s 100th Episealer® Femoral Twin implant demonstrates rapid clinical adoption
  • Episurf Medical’s 50th Episealer® implant in Belgium
  • Episurf Medical reached milestone of 250 implants sold
  • Episurf Medical reported a brief clinical update
  • Management group changes in Episurf Medical were announced
  • Episurf Medical became an approved supplier to Spire Healthcare, one of the UK’s largest Independent hospital providers
  • Case-report with clinical data of Episealer® patient was published
  • Another preclinical paper on the Episealer® Implant published
  • Dennis D. Stripe re-assumed the position as non-executive chairman of the board

Significant events after the third quarter

  • Episurf Medical obtained another new patent in China
  • Fredrik Zetterberg appointed Head of Marketing for Episurf Medical

Link to the report

For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com